Tim F Greten - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Tim F Greten

Showing results (111-120 of 223) with videos related to

Pageof 23

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinomaFirouzeh Korangy, Lars A Ormandy, Jörg S Bleck, et al.

Gastroenterology|May 20, 2008

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cellsBastian Hoechst, Lars A Ormandy, Matthias Ballmaier, et al.

Oncoimmunology|November 22, 2012

Primary sterile necrotic cells fail to cross-prime CD8(+) T cellsJaba Gamrekelashvili, Lars A Ormandy, Markus M Heimesaat, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 9, 2010

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCCTim F Greten, Lars A Ormandy, Annika Fikuart, et al.

Journal of Vascular and Interventional Radiology : JVIR|July 27, 2013

Personalized oncology in interventional radiologyNadine Abi-Jaoudeh, Austin G Duffy, Tim F Greten, et al.

Journal of Gastroenterology and Hepatology|May 22, 2016

Specific immunotherapy in hepatocellular cancer: A systematic reviewBehnoud Baradaran Noveiry, Armin Hirbod-Mobarakeh, Nastaran Khalili, et al.

Hepatology (Baltimore, Md.)|April 24, 2023

Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m 6 A-mediated epitranscriptomic regulationMan Hsin Hung, Ching Wen Chang, Kathy Cheng Wang, et al.

Hepatology Communications|October 7, 2020

Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database AnalysisGagandeep Brar, Tim F Greten, Barry I Graubard, et al.

Cancer Immunology Research|February 1, 2015

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver DamageJosé Medina-Echeverz, Chi Ma, Austin G Duffy, et al.

JHEP Reports : Innovation in Hepatology|May 9, 2025

Hepatic immune environment differences among common mouse strains in models of MASH and liver cancerPatrick Huang, Francisco J Rodriguez-Matos, Jonathan Qi, et al.

Pageof 23

Search research articles

Showing results (111-120 of 223) with videos related to

Sort By:

Pageof 23

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinomaFirouzeh Korangy, Lars A Ormandy, Jörg S Bleck, et al.

Gastroenterology|May 20, 2008

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cellsBastian Hoechst, Lars A Ormandy, Matthias Ballmaier, et al.

Oncoimmunology|November 22, 2012

Primary sterile necrotic cells fail to cross-prime CD8(+) T cellsJaba Gamrekelashvili, Lars A Ormandy, Markus M Heimesaat, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 9, 2010

Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCCTim F Greten, Lars A Ormandy, Annika Fikuart, et al.

Journal of Vascular and Interventional Radiology : JVIR|July 27, 2013

Personalized oncology in interventional radiologyNadine Abi-Jaoudeh, Austin G Duffy, Tim F Greten, et al.

Journal of Gastroenterology and Hepatology|May 22, 2016

Specific immunotherapy in hepatocellular cancer: A systematic reviewBehnoud Baradaran Noveiry, Armin Hirbod-Mobarakeh, Nastaran Khalili, et al.

Hepatology (Baltimore, Md.)|April 24, 2023

Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m 6 A-mediated epitranscriptomic regulationMan Hsin Hung, Ching Wen Chang, Kathy Cheng Wang, et al.

Hepatology Communications|October 7, 2020

Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database AnalysisGagandeep Brar, Tim F Greten, Barry I Graubard, et al.

Cancer Immunology Research|February 1, 2015

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver DamageJosé Medina-Echeverz, Chi Ma, Austin G Duffy, et al.

JHEP Reports : Innovation in Hepatology|May 9, 2025

Hepatic immune environment differences among common mouse strains in models of MASH and liver cancerPatrick Huang, Francisco J Rodriguez-Matos, Jonathan Qi, et al.

Pageof 23